GlassScriptPhysician profile
Jonathan Billy Vignes
NPI 1992187090
$8,560.87
in general payments reported to CMS, 2019-2025
27 companies · $5,184 in 2025
The $5,184 reported for 2025 was more than what 93% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $547 · 2023: $1,364 · 2024: $1,465 · 2025: $5,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,362 · Education: $2,500 · Travel and Lodging: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,361.90 |
| Education | $2,500.00 |
| Travel and Lodging | $151.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,775.52 | 2024-2025 | |
| Glaxosmithkline, LLC. | $1,382.01 | 2022-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,072.33 | 2022-2025 | Fasenra, Tezspire, Breztri |
| Genzyme Corporation | $792.24 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.05 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mallinckrodt Hospital Products INC. | $310.90 | 2022-2025 | Acthar |
| Merck Sharp & Dohme LLC | $239.89 | 2023-2025 | Winrevair, Zerbaxa |
| Insmed, INC. | $233.97 | 2023-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $207.23 | 2022-2025 | Dupixent |
| Grifols USA, LLC | $198.98 | 2023-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $152.35 | 2025 | Ohtuvayre |
| Amgen INC. | $137.46 | 2022-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $106.68 | 2022-2024 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $82.15 | 2022-2023 | |
| Mylan Specialty L.P. | $77.71 | 2022-2023 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $76.88 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $42.87 | 2023 | |
| United Therapeutics Corporation | $41.15 | 2022-2023 | Tyvaso |
| Baxter Healthcare | $38.72 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $32.46 | 2023-2025 | Vest Therapy Und |
| Ani Pharmaceuticals, INC. | $31.13 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $25.21 | 2022 | |
| Liquidia Technologies, INC. | $22.60 | 2025 | Yutrepia |
| La Jolla Pharmaceutical Company | $17.29 | 2025 | Giapreza |
| Inogen, INC. | $16.93 | 2024 | |
| Phadia US INC. | $16.70 | 2022 | |
| Genentech USA, INC. | $13.46 | 2023 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Vignes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.